| 前收盘价格 | 60.85 |
| 收盘价格 | 60.75 |
| 成交量 | 1,454,752 |
| 平均成交量 (3个月) | 7,176,118 |
| 市值 | 54,526,603,264 |
| 预期市盈率 (P/E Forward) | 357.14 |
| 价格/销量 (P/S) | 24.82 |
| 股市价格/股市净资产 (P/B) | 9.50 |
| 52周波幅 | |
| 利润日期 | 28 Aug 2024 |
| 营业毛利率 | -39.24% |
| 营业利益率 (TTM) | -37.31% |
| 稀释每股收益 (EPS TTM) | -0.920 |
| 季度收入增长率 (YOY) | -72.10% |
| 总债务/股东权益 (D/E MRQ) | 64.54% |
| 流动比率 (MRQ) | 4.79 |
| 营业现金流 (OCF TTM) | -749.97 M |
| 杠杆自由现金流 (LFCF TTM) | -3.26 B |
| 资产报酬率 (ROA TTM) | -6.01% |
| 股东权益报酬率 (ROE TTM) | -15.63% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | AKESO | - | - |
AIStockmoo 评分
1.5
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.50 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
| BEIGENE | 195 B | - | - | 6.93 |
| WUXI BIO | 82 B | - | 29.13 | 1.87 |
| SINO BIOPHARM | 52 B | 1.92% | 22.08 | 1.48 |
| PHARMARON | 46 B | 1.60% | 12.70 | 1.66 |
|
Akeso Inc is an investment holding company. The Company’s subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Growth |
| 内部持股比例 | 24.63% |
| 机构持股比例 | 28.02% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合